Summary
Global Markets Direct’s, ‘Green Cross Corporation - Product Pipeline Review - 2016’, provides an overview of the Green Cross Corporation’s pharmaceutical research and development focus.
The report provides comprehensive information on the therapeutics under development by Green Cross Corporation, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and the dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the pipeline therapeutic landscape of Green Cross Corporation
- The report provides overview of Green Cross Corporation including its business description, key facts, and locations and subsidiaries
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report assesses Green Cross Corporation’s pipeline therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report features Green Cross Corporation’s out-licensed and partnered product portfolio and summarizes its dormant and discontinued projects
Reasons to buy
- Evaluate Green Cross Corporation’s strategic position with total access to detailed information on its product pipeline
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Green Cross Corporation
- Identify potential new clients or partners in the target demographic
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Green Cross Corporation’s pipeline depth and focus of pipeline therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
'
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Green Cross Corporation Snapshot 6
Green Cross Corporation Overview 6
Key Information 6
Key Facts 6
Green Cross Corporation - Research and Development Overview 7
Key Therapeutic Areas 7
Green Cross Corporation - Pipeline Review 10
Pipeline Products by Stage of Development 10
Pipeline Products - Monotherapy 11
Pipeline Products - Partnered Products 12
Partnered Products/Combination Treatment Modalities 13
Green Cross Corporation - Pipeline Products Glance 14
Green Cross Corporation - Late Stage Pipeline Products 14
Pre-Registration Products/Combination Treatment Modalities 14
Phase III Products/Combination Treatment Modalities 15
Green Cross Corporation - Clinical Stage Pipeline Products 16
Phase II Products/Combination Treatment Modalities 16
Phase I Products/Combination Treatment Modalities 17
Green Cross Corporation - Early Stage Pipeline Products 18
Preclinical Products/Combination Treatment Modalities 18
Discovery Products/Combination Treatment Modalities 19
Green Cross Corporation - Drug Profiles 20
immune globulin (human) 20
Product Description 20
Mechanism of Action 20
R&D Progress 20
antihemophilic factor (recombinant) 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
GC-1107 22
Product Description 22
Mechanism of Action 22
R&D Progress 22
GC-3106A 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
idursulfase beta 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
margetuximab 26
Product Description 26
Mechanism of Action 26
R&D Progress 26
GC-1102 28
Product Description 28
Mechanism of Action 28
R&D Progress 28
GC-1109 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
GC-1118A 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
GC-3111A 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GCC-2107 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
MG-1111 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
Monoclonal Antibody Conjugate to Target HER2 for Breast Cancer 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
LCB-141XXX 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
Green Cross Corporation - Pipeline Analysis 36
Green Cross Corporation - Pipeline Products by Target 36
Green Cross Corporation - Pipeline Products by Route of Administration 38
Green Cross Corporation - Pipeline Products by Molecule Type 39
Green Cross Corporation - Pipeline Products by Mechanism of Action 40
Green Cross Corporation - Recent Pipeline Updates 41
Green Cross Corporation - Dormant Projects 45
Green Cross Corporation - Company Statement 46
Green Cross Corporation - Locations And Subsidiaries 47
Head Office 47
Other Locations & Subsidiaries 47
Appendix 49
Methodology 49
Coverage 49
Secondary Research 49
Primary Research 49
Expert Panel Validation 49
Contact Us 49
Disclaimer 50
List of Tables
Green Cross Corporation, Key Information 6
Green Cross Corporation, Key Facts 6
Green Cross Corporation - Pipeline by Indication, 2016 8
Green Cross Corporation - Pipeline by Stage of Development, 2016 10
Green Cross Corporation - Monotherapy Products in Pipeline, 2016 11
Green Cross Corporation - Partnered Products in Pipeline, 2016 12
Green Cross Corporation - Partnered Products/ Combination Treatment Modalities, 2016 13
Green Cross Corporation - Pre-Registration, 2016 14
Green Cross Corporation - Phase III, 2016 15
Green Cross Corporation - Phase II, 2016 16
Green Cross Corporation - Phase I, 2016 17
Green Cross Corporation - Preclinical, 2016 18
Green Cross Corporation - Discovery, 2016 19
Green Cross Corporation - Pipeline by Target, 2016 37
Green Cross Corporation - Pipeline by Route of Administration, 2016 38
Green Cross Corporation - Pipeline by Molecule Type, 2016 39
Green Cross Corporation - Pipeline Products by Mechanism of Action, 2016 40
Green Cross Corporation - Recent Pipeline Updates, 2016 41
Green Cross Corporation - Dormant Developmental Projects,2016 45
Green Cross Corporation, Other Locations 47
Green Cross Corporation, Subsidiaries 48
List of Figures
Green Cross Corporation - Pipeline by Top 10 Indication, 2016 8
Green Cross Corporation - Pipeline by Stage of Development, 2016 10
Green Cross Corporation - Monotherapy Products in Pipeline, 2016 11
Green Cross Corporation - Partnered Products in Pipeline, 2016 12
Green Cross Corporation - Pipeline by Top 10 Target, 2016 36
Green Cross Corporation - Pipeline by Route of Administration, 2016 38
Green Cross Corporation - Pipeline by Top 10 Molecule Type, 2016 39
Green Cross Corporation - Pipeline Products by Mechanism of Action, 2016 40
